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Cell migrationmechanisms of activation, as well as the endogenous regulators for the non-
selective cationic channel TRPV2 are not known so far. In the present work we report that endogenous
lysophospholipids such as lysophosphatidylcholine (LPC) and lysophosphatidylinositol (LPI) induce a calcium
inﬂux via TRPV2 channel. This activation is dependent on the length of the side-chain and the nature of the
lysophospholipid head-group. TRPV2-mediated calcium uptake stimulated by LPC and LPI occurred via Gq/
Go-protein and phosphatidylinositol-3,4 kinase (PI3,4K) signalling. We have shown that the mechanism of
TRPV2 activation induced by LPC and LPI is due to the TRPV2 channel translocation to the plasma membrane.
The activation of TRPV2 channel by LPC and LPI leads to an increase in the cell migration of the prostate
cancer cell line PC3. We have demonstrated that TRPV2 is directly involved in both steady-state and
lysophospholipid-stimulated cancer cell migration. Thus, for the ﬁrst time, we have identiﬁed one of the
natural regulators of TRPV2 channel, one of the mechanisms of TRPV2 activation and regulation, as well as its
pathophysiological role in cancer.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Calcium constitutes an essential intracellular messenger to a
plethora of cell signal transduction pathways and a number of
important physiological functions. In non-excitable cells, transient
receptor potential (TRP) channels play an important role in cytosolic
calcium regulation [1]. Given the importance of calcium signalling in
all cell types, it is not surprising that dysfunctions in Ca2+-permeable
channels may eventually contribute to the pathogenesis of different
diseases. The TRP family of channels is divided into seven related
subfamilies: TRPC, TRPV, TRPM, TRPP, TRPN, TRPA and TRPML [2–4].
TRP channels have received considerable attention over the past
decade and a number of remarkable properties and modes of
regulation have been discovered for most of them, allowing us to
understand such fundamental physiological functions as thermosen-
sing, taste or calcium absorption [5]. However, TRPV2 (initially named
VRL-1), a member of the TRP vanilloid, TRPV, channel subfamily,ie Cellulaire Inserm U-800,
e. Tel.: +33 3 20 33 64 23;
. Prevarsakaya).
l rights reserved.remains one of the most mysterious, since both its physiological and/
or pathophysiological function, the mechanisms of its activation and
the identity of the endogenous channel regulators are still unknown.
TRPV2 is expressed in sensory neurons and was initially detected
in tissues having no role in thermosensation, such as the digestive
tract and prostate [6,7]. Furthermore, in non-neuronal cells mechan-
isms other than temperature have been reported to activate TRPV2,
such as the chemotactic peptide fMetLeuPhe [8] or growth factors
inducing dynamic insertion into the plasma membrane [9], regulation
by a phosphatidylinositol-3 kinase (PI3K) dependent pathway [10], or
mechano- and osmotic stimuli [11,12]. In addition, despite the ﬁndings
that 2-APB (2-aminoethoxydiphenyl borate) [13] and noxious heat
(N52 °C) activate rat and mouse TRPV2 (r, mTRPV2), neither of these
stimuli has been shown to activate human TRPV2 (hTRPV2) [14,15].
Several endogenous molecules have been shown to activate TRP
channels including membrane phospholipids, such as phosphatidylino-
sitol 4,5-bisphosphate (PIP2) or lysophospholipids (LPC and LPI). It has
recently been shown that TRPC5 and TRPM8 could be activated by
lysophospholipids [16,17], and a number of TRP channels (TRPV1, TRPV5,
TRPM4, TRPM5, TRPM7, TRPM8) could be regulated by PIP2 and fatty
acid derivatives [18]. In an effort to further understand TRPV2 function
and physiological activation, it was our aim to investigate TRPV2-
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identiﬁed some lysophospholipids as new physiological stimuli for
TRPV2 channel. This mechanism is very important since it has been
suggested that lysophospholipids have a range of physiological and
pathological effects [19,20], including the stimulation of cancer cell
migration [21,22]. The latter has also been a focus of our studies.
2. Experimental procedures
2.1. Chemicals and lipid preparation
LPCs, a mix of fatty acids (Lipid Standards: Fatty Acid Methyl Ester
mixtures), LPI (L-α-lysophosphatidylinositol), LPE (3-sn-Lysopho-
sphatidylethanolamine), LPA (Oleoyl-L-α-lysophosphatidic acid
sodium salt) and S1P (Sphingosine 1-phosphate), were dissolved
into methanol. The ﬁnal bath solvent concentration was ≤0.1% and
was present in the control period prior to application of the lipid
molecule. No solvent effects were evident (e.g. see Figs. 1I and 2G).
L-α-Lysophosphatidylcholine (soybean), L-α-caproyl lysophosphati-
dylcholine (LPC C6:0), L-α-lauroyl lysophosphatidylcholine (LPC
C12:0), 3-sn-1-myristoyl-lysophosphatidylcholine (LPC C14:0), L-α-
palmitoyl lysophosphatidylcholine (LPC C16:0), 1-Stearoyl-sn-gly-
cero-3-phosphocholine (LPC C18:0), 1-Oleoyl-sn-glycero-3-phospho-
choline (LPC C18:1), LPI (L-α-lysophosphatidylinositol soybean), LPE
(3-sn-Lysophosphatidylethanolamine), LPA (Oleoyl-L-α-lysophospha-
tidic acid sodium salt), S1P (Sphingosine 1-phosphate), a mix of
fatty acids (Lipid Standards: Fatty Acid Methyl Ester mixtures),
choline (2-hydroxyethyl trimethylammonium hydroxide), arachido-
nic acid, pertussis toxin (PTX), wortmannin, and LY294002 were
purchased from Sigma. If not mentioned otherwise, LPC (LPC CTL)
corresponds to L-α-Lysophosphatidylcholine (soybean).
2.2. Cell culture
Human Embryonic Kidney 293 (HEK293) and Prostate Carcinoma 3
(PC3) cells were cultured as previously described [23,24]. Chinese
Hamster Ovary K1 (CHO-K1) and stable CHO cell lines expressing
mouse TRPV2 (clone IIE11) were cultured as previously described [15].
2.3. Generation of shTRPV2 vectors
Hybridized oligonucleotides were cloned in pSilencer 4.1-CMV
puro (Ambion, Courtaboeuf, France) following the manufacturer's
instructions and were deﬁned as shTRPV2-1 (sense 5′-GGTAA-
GACGTGCCTGATGA-3′) and shTRPV2-2 (sense 5′ TAAGAGTCAACCT-
CAACTA-3′). Silencing efﬁciency was checked by western-blotting and
PCR.
2.4. Nucleofection
Transfection of HEK293 or PC3 cells with hTRPV2-GFP or with
shTRPV2-1 and -2 was carried out using Nucleofector, as recom-
mended by themanufacturer (Amaxa GmbH, Köln, Germany). 3 μg of a
vector were transfected into 2 million trypsinized cells, which were
then seeded into a T75 ﬂask and on glass slips for 72 h. For HEK293,
cells were always co-nucleofected with a plasmid encoding two
shRNAs TRPV2 (HEKhTRPV2-shV2 I or II) used to knockdown hTRPV2
channel expression or with pSilencer used as a negative control
(HEKhTRPV2). Expression of hTRPV2-GFP channel was detected 72 h
after nucleofection by GFP ﬂuorescence using HEKhTRPV2 cells.
2.5. Reverse transcription-PCR
Total RNAs were isolated from PC3 cells followed by PCR as
previously described [23]. Primers used are listed in Table 1. Then,
density measurements were performed with “Quantity one” software(Biorad) and the data were analyzed using Origin 7.0 (Microcal
Software Inc., Northampton, MA, USA).
2.6. Immunodetection
HEK293 and CHO cells were ﬁxed with 4% formaldehyde-1X PBS
(Phosphate Buffer Saline) for 15 min, washed three times, then
permeabilized in PBS-gelatin 1.2% complemented with 0.01% Tween
20 and 100 mM glycine for 30 min at 37 °C. Subsequently, cells were
incubated with primary antibodies: (1/250) rabbit polyclonal anti-
hTRPV2 antibody for HEK293 and (1/250) rabbit polyclonal anti-
mTRPV2 antibody for CHO cells, (1/25) in PBS-gelatin at 37 °C for 1.5 h.
After thorough washes, the slides were treated with the correspond-
ing anti-rabbit or anti-mouse IgG, coupled with Alexa ﬂuor 488-
labeleld (Molecular probes, dilution: 1/2000) diluted in PBS-gelatin
for 1 h at room temperature. After two washes, the slides were
mounted with Mowiol®. Fluorescence analysis was carried out using a
Zeiss LSM 510 confocal microscope and analysis software (AIM 3.2,
Zeiss), as previously described [23].
2.7. Ca2+ measurements using Fura-2 AM
Prior to ﬂuorescence measurements, cells were trypsinized and
transferred to glass slips. Cells were used 3 days after trypsinization.
The medium was replaced every 48 h. The culture medium was
replaced by an HBSS solution containing 142 mM NaCl, 5.6 mM KCl,
1mMMgCl2, 2mMCaCl2, 0.34mMNa2HPO4, 0.44mMKH2PO4,10mM
HEPES, and 5.6 mM glucose. The osmolarity and pH of this solution
were adjusted to 310 mOsm l−1 and 7.4, respectively. When a Ca2+ free
medium was required, CaCl2 was omitted and replaced by equimolar
MgCl2. Dye loading was achieved by transferring the cells into a
standard HBSS solution containing 1 mM Fura-2 AM (Calbiochem,
Meudon, France) as described previously [25].Δ[Ca2+ cyt] corresponds
to an amplitude response ([Ca2+ cyt]max− [Ca2+ cyt]min).
2.8. Electrophysiological recordings
Macroscopic currents were recorded at room temperature (22 °C)
by the whole-cell patch-clamp technique using an Axopatch 200B
ampliﬁer (Molecular Devices). The extracellular solution contained
150 mM NaCl, 6 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, and 10 mM
HEPES, with pH adjusted to 7.4 with NaOH. The resistance of the
patch pipettes fabricated from borosilicate glass capillaries (World
Precision Instruments, Inc., Sarasota, FL) when ﬁlled with the
intracellular solution was 2-3 MΩ for the whole cell recordings
The internal solution contained 150 mM KCl, 5 mM EGTA, 10 mM
HEPES, 3 mM magnesium-ATP, with pH adjusted to 7.2 with KOH. In
the whole cell experiments, series resistance was compensated for
by about 70%. Currents were ﬁltered at 1 or 2 kHz and sampled at
10 kHz. For temperature control and solution exchange, the TC1-
SL25 system (Bioscience Tools, San Diego, CA) was used with the
temperature probe placed near the patch pipette tip. The system
provided a temperature stability of at least 0.2 °C. Membrane
current recordings obtained were analyzed and plotted using the
pCLAMP 9 (Axon Instruments, Inc.) and Origin 5 software (Microcal
Software Inc.).
2.9. Antibody production
Rabbit polyclonal antibody anti-hTRPV2 and anti-mTRPV2 were
produced in the laboratory headed by Dr. Rassendren (CNRS UMR
5203, INSERM U661, Montpellier, France). The polypeptide ASEE-
NYVPVQLLQS corresponding to 740–763 aa of the C-terminus
sequence of the human TRPV2 channel (NM_016113) was injected
into rabbit to produce a polyclonal antibody anti-hTRPV2. The
polypeptide IDRDSGNPQPLVNAQ corresponding to 137–151 aa of the
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produce polyclonal antibody anti-mTRPV2.
2.10. Immunoblotting
After treatment the cells were rinsed with a NaCl solution
(150 mM) and lysed in an ice-cold homogenizing buffer (pH 7.2)
containing 20 mM PO4Na2K, 1% Triton X100, 1% sodium desoxycho-
late, 5 mM EDTA and a protease inhibitor cocktail (P8340, Sigma) for
30 min at 4 °C. Homogenates were cleared by centrifugation at
16,000 g for 10 min and the protein content in the supernatants was
determined using the BCAmethod (Pierce, Chemical Co., Rockford, IL).
4 μg of total proteins were analyzed using 10% SDS-polyacrylamide gel
electrophoresis. After the transfer onto a PVDF membrane using a
semi-dry electroblotter, the membrane was cut into thin strips that
were further processed for immunodetection. The strips were blocked
in 5% non-fat dry milk in TBST (15 mM Tris buffer (pH 8), 140 mM
NaCl, 0.05% Tween 20), washed three times, then incubated with a
polyclonal anti-mTRPV2 antibody (rabbit, 1/250), or with a polyclonal
anti-hTRPV2 antibody (rabbit, 1/250) as previously described [15], or
with a polyclonal anti-GFP antibody (rabbit, 1/500 catalog no.
AB3080P; Chemicon). After washing, blots were incubated for 1 h
with the corresponding horseradish peroxydase-linked secondary
antibody and processed for chemoluminescent detection (Pierce,
Chemical Co., Rockford, IL) according to the manufacturer's instruc-
tions (Eastman Kodak Co., Rochester, NY). Membranes were re-
blotted twice with a monoclonal antibody anti-actin (mouse, 1/500
catalog no. MS-1295-P; Neomarkers), or with a monoclonal antibody
anti-calnexin (mouse, 1/2000 catalog no. MAB 3126; Chemicon). The
bands on the membrane were visualized using the enhanced
chemiluminescence method (Pierce Biotechnologies Inc.). Densito-
metric analysis was performed using a Bio-Rad image acquisition
system (Bio-Rad Laboratories).
2.11. Biotinylation assay
TRPV2 cell surface expressionwas analyzed in HEK293 cells as well
as in the stable cell line CHO mTRPV2 transiently transfected (72 h)
with hTRPV2-GFP. After treatmentwith LPC or LPI (data not shown) for
15 min, cells were washed twice with ice-cold PBS containing 1 mM
MgCl2 and 0.5 mM CaCl2 (PBS-CM) and subjected to cell surface
biotinylation as described previously [26]. Biotinylated proteins were
precipitated using neutravidin-agarose beads (Pierce, Rockford, IL,
USA) and eluted with SDS-PAGE loading buffer. TRPV2 expression
analysiswas analyzed by immunoblottingwith antibody anti-mTRPV2
or anti-hTRPV2 as described in the Immunoblotting section above.
2.12. Migration protocol
PC3 nucleofected cells were seeded onto the top of Transwell® cell
culture inserts with 8.0 μm pore size (Falcon), at a density of 30,000
cells per well (24-well format) in serum-free culture medium. Cells
were stimulated tomigrate across the ﬁlters by providing 10% fetal calf
serum as a chemoattractant in the assay chambers beneath the inserts.
After 2 h, almost two-thirds of the cells were adherent to each ﬁlter in
the inserts. 10 μM LPC or LPI was then added to the upper chamber (orFig. 1.mTRPV2 is activated by LPC and LPI. (A) Immunoblotting of CHO-mTRPV2 cell lysates w
92 kDa and one not glycosylated of 83 kDa. The numbers indicated under the mTRPV2 pa
immuno-localisation of TRPV2 in CHO-mTRPV2 cells. (C) Higher magniﬁcation revealed th
control. (E) Representative traces measured by Ca2+ imaging showing the effects of high tem
(N=90; n=3). (F) Representative traces measured by Ca2+ imaging showing the effect of LP
imaging experiment showing the effect of LPI 10 μM in CHO mTRPV2 cells (N=90; n=3), no
response to LPC 10 μM (N=90; n=3), LPI 10 μM (N=90; n=3) andmethanol (MeOH) vehicle (N
(measured at ±100 mV) changes in response to LPC (3 μM) (n=10) in CHO-mTRPV2 cells. Exp
relationships demonstrating the activation of mTRPV2 current by LPC (3 μM). (K) Time cours
response to 2-APB 1 mM in CHO-mTRPV2 cells.water as a control solvent). After 26 h incubation at 37 °C, non
migratory cells were removed from the top of the ﬁlter by scraping,
while cells that had migrated through the ﬁlter pores to the lower face
of the inserts were ﬁxed in 4% paraformaldehyde in PBS, and stained
with Hoechst (5 mg/L in PBS). Cells under each ﬁlter were counted on
ﬁve random examination ﬁelds (×200) using a Leica DMIRB inverted
microscope. Data are expressed as means of 4 wells±SEs.
2.13. Data analysis
Results are expressed as means±SEM. Plots were produced using
Origin5.0 (Microcal Software, Inc). N corresponds to a number of
cells; n corresponds to a number of independent experiments. Each
experiment was repeated at least three times. The Turkey–Kramer
test was used for statistical comparison among means and differ-
ences. ⁎—corresponds to Pb0.05; ⁎⁎—corresponds to Pb0.01; ⁎⁎⁎—
corresponds to Pb0.005. Pb0.05 was considered as signiﬁcant.
3. Results
3.1. Lysophospholipids activate TRPV2 channel
We have previously reported that the transient transfection of
TRPV2 results in the high levels of its protein expression leading to
cellular toxicity [10]. To avoid this problem, we have used a stable
CHO cell line expressing mTRPV2 channel [10,15]. Prior to functional
studies, we conﬁrmed mTRPV2 protein expression by immunoblot-
ting (Fig. 1A) and its plasma membrane localisation by immuno-
ﬂuorescence (Fig. 1B, C and D). The cytoplasmic [Ca2+] was measured
by the microscopy-based single-cell imaging technique using the
ratiometric Ca2+ indicator dye fura-2. To induce Ca2+ inﬂux via
mTRPV2 and to control the channel functionality, preheated solution
was used (Fig. 1E).
Subsequently, we studied the effect of LPC and LPI on CHO-
mTRPV2 cells. Application of 10 μM LPC and 10 μM LPI induced a
sustained [Ca2+]cyt increase after few minutes in CHO-mTRPV2 cells
(Fig. 1F and G, mean time delay was 66 s±33 s for LPC and 72 s±24 s
for LPI). Indeed, stimulation by LPC and LPI induced a [Ca2+]cyt increase
of 810 nM±35 nM and 646 nM±31 nM, respectively, in CHOmTRPV2
cells (Fig. 1H). Extracellular application of LPC activated an outwardly
rectifying membrane current in CHOmTRPV2 cells (Fig. 1I, J), which by
its biophysical properties was similar to ITRPV2 induced by 2-APB [15],
thereby demonstrating that lysophospholipids are able to activate
TRPV2 from the outside of the membrane. Moreover, 10 μM LPC
induced potentiation on the activation of mTRPV2 current already
pre-activated by 1mM 2-APB (Fig. 1K). Different concentrations of LPC
and LPI were examined by calcium imaging technique (see the dose
effects of LPC and LPI which are presented in the supplementary data,
Figs. 1 and 2, respectively). Of them, the lowest effective concentration
of 10 μM was used in this study. LPC and LPI solvent (MeOH) had no
effect on the cells (Fig. 1H).
To check if lysophospholipids could be a common activator for both
mouse and human TRPV2 homologues, we tested LPC and LPI effects on
HEK293 cells overexpressing hTRPV2. Thus, HEK293 cells were
nucleofected with hTRPV2-GFP. The expression of hTRPV2-GFP channel
was detected 72 h after nucleofection by GFP ﬂuorescence using HEK-ith the anti-mTRPV2 antibody showing two immunopositive bands: one glycosylated of
nel are the relative integrative intensities of the bands. (B) Confocal images showing
e plasma membrane localisation of the channel, (D) CHO cells are used as a negative
peratures (indicated by red bars) in CHO-mTRPV2 (N=90; n=3) and CHO control cells
C 10 μM in CHO mTRPV2 cells (n=90) versus CHO control cells (N=90; n=3). (G) Ca2+
t in CHO control cells (N=90; n=3). (H) Comparative graph showing maximal mean in
=90; n=3) between CHO-mTRPV2 and CHO control cells. (I) Time courses of the current
eriments shown were conducted at 22 °C. (J) Representative voltage ramp-derived I–V
es of the current (measured at +100 mV) changes in response to LPC (10 μM) (n=5) after
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Table 1
List of primers used for RT-PCR ampliﬁcations
5′-forward-3′ 5′-reverse-3′ Expected product size (bp) Accession number
TRPV2 AAAGGGAACAGGTGCCAGTCA TCCCACTGCTTGGTGCAAGCG 475 NM_016113.3
β-actin CAGAGCAAGAGAGGCATCCT GTTGAAGGTCTCAAACATGATC 210 NM_001101
533M. Monet et al. / Biochimica et Biophysica Acta 1793 (2009) 528–539hTRPV2 cells (Fig. 2A, I). In order to speciﬁcally reduce hTRPV2
expression, we used a co-nucleofection protocol with shRNA-TRPV2 I
or II. TRPV2expressionwasdownregulated by 20% in shRNATRPV2 I (Fig.
2A, II) and by 100% in shRNATRPV2 II (Fig. 2A, III) expressing cells. TRPV2
silencingwas conﬁrmed by immunoblottingwith anti-GFPantibody. For
other experiments, we used shRNA TRPV2 II since it has shown the
highest TRPV2 silencing level (Fig. 2A, IV). Immuno-histochemical
analysis of HEK293 cells nucleofected as described in Experimental
Procedures conﬁrmed that hTRPV2 is co-localised with a GFP protein
(Fig. 2B, I). The GFP protein (Fig. 2B, II) was detected in hTRPV2-positive
cells, with the intense intracellular labelling exactly overlapping the
expression of this channel (Fig. 2B, III).
In Ca2+ imaging experiments, no difference was observed in [Ca2+]cyt
increased by high temperature. High temperature induced a [Ca2+]cyt
increase with a maximal amplitude of 206 nM±3 nM in HEKh-TRPV2
cells and 175±4 nM in HEK-hTRPV2-shTRPV2 II cells, respectively (Fig.
2C). The effects of 2-APB have been also investigated on calcium
responses mediated by human TRPV2 channel by patch clamp, but any
current was observed in HEKh-TRPV2 cells following 2-APB application
(not shown; n=4). Therefore, high temperatures as well as 2-APB failed
to activate the human homologue of TRPV2 [14].
However, 10 μM LPC (706 nM±79 nM; Fig. 2D, F) and 10 μM LPI
(660 nM±53 nM; Fig. 2E, F) induced a [Ca2+]cyt increase only in HEKh-
TRPV2 cells, but not in HEKh-TRPV2-shTRPV2 II. Moreover, application
of LPC (3 μM) in HEKh-TRPV2 cells induced a current (Fig. 2G, H) which
was similar to that observed in CHOmTRPV2 cells (Fig. 1I, J).
3.2. Lysophospholipids chain length and composition deﬁne
TRPV2 stimulation
Lysophospholipids consist of a polar head-group and an unsatu-
rated chain of a fatty acid. LPC and LPI have choline and inositol
head-groups, respectively. We therefore checked whether the head-
groups and the unsaturated chain lengths exerted distinct effects on
TRPV2 activity. We demonstrated that a mix of fatty acids had no
effect on either mTRPV2 channel (Fig. 3A) or hTRPV2 channel (Fig.
3B). We have also shown that choline had no effect on CHOm-TRPV2
cells (Fig. 3A) nor on HEK-hTRPV2 cells (Fig. 3B). Additional
lysophospholipids such as lysophosphatic acid (LPA) or Lysopho-
sphatidylethanolamine (LPE) and sphingolipids such as Sphingosine-
1-phosphate (S1P) have been examined. None of these had any
signiﬁcant effect on CHO-mTRPV2 cells (Fig. 3A, 9±2 nM for LPA,
59 nM±9 nM for S1P,15 nM±9 nM for LPE and 662 nM±37 nM for LPC)
nor on HEK-hTRPV2 cells (Fig. 3B, 3±1 nM for LPA, 36 nM±10 nM for
S1P, 5 nM±2 nM for LPE and 631 nM±79 nM for LPC, respectively).
Thus, to stimulate the TRPV2 channel, lysophospholipids should
exhibit a precise combination of a head-group and a side chain. WeFig. 2. LPC and LPI activate hTRPV2 channel. (A) Cells nucleofected with hTRPV2-GFP and th
emission. Cells co-nucleofected with hTRPV2-GFP and shRNA TRPV2 I (HEKhTRPV2-shV2 I) (I
GFP+shRNA TRPV2 II (HEKhTRPV2-shV2 II) (III). Immunoblotting of HEK-hTRPV2, HEK-hTRP
after nucleofection. The numbers indicated under the GFP panel are the relative integrative
and hTRPV2 (III) detected by anti-hTRPV2 antibody. (C) Representative traces measured by
hTRPV2 (N=90; n=3) and HEK-hTRPV2-shV2 II control cells (N=90; n=3). (D) Representativ
(N=60; n=3), and in HEK-hTRPV2-shV2 II control cells (N=60; n=3). (E) Ca2+ imaging expe
hTRPV2-shV2 II control cells (N=60; n=3). (F) Comparative graph showing maximal mean
vehicle (N=60; n=3) between HEK hTRPV2 and HEK-hTRPV2 shV2 II cells. (G) Time courses o
cells (n=7). (H) Representative voltage ramp-derived I–V relationships demonstrating the ahave demonstrated that chain lengths greater than 12 carbons are
needed to stimulate mTRPV2 (6 nM±4 nM for LPC C6:0; 7 nM±2 nM
for LPC C12:0; 73 nM±8 nM for LPC C14:0; 573 nM±43 nM for LPC
C16:0; 737 nM±39 nM for LPC C18:0; 692 nM±34 nM for LPC C18:1;
and 744 nM±33 nM for LPC CTL in CHO-mTRPV2; Fig. 3C) as well as
hTRPV2 (1 nM±6 nM for LPC C6:0; 3 nM±1 nM for LPC C12:0; 61 nM±
13 nM for LPC C14:0; 454 nM±59 nM for LPC C16:0; 585 nM±70 nM
for LPC C18:0; 529 nM±33 nM for LPC C18:1; and 628 nM±38 nM for
LPC CTL in HEKh-TRPV2; Fig. 3D).
3.3. LPC induces Ca2+ inﬂux through TRPV2 via the G-protein and the
PI3,4K pathways
In order to discriminate the origin of Ca2+ increase induced by
lysophospholipids, we tested LPC and LPI (data not shown) on CHO-
mTRPV2 and HEK-hTRPV2 without Ca2+ in the extracellular medium
(0 Ca2+). LPC did not induce signiﬁcant depletion of endoplasmic
reticulum (ER) Ca2+ stores in CHO-mTRPV2 (Fig. 4A, C 61 nM±27 nM)
and HEK-hTRPV2 (Fig. 4B, C 10 nM±3 nM) cells. Application of 2 mM
Ca2+ (2Ca2+) in the extracellular medium resulted in a massive Ca2+
entry with an amplitude of 683 nM±58 nM (Fig. 4C) in CHO-mTRPV2
and of 530 nM±30 nM (Fig. 4C) in HEK-hTRPV2 cells. Thus lysopho-
spholipids activate both mTRPV2 and hTRPV2 channels presented in
the plasma membrane (Figs. 1B, C and 2Aa) inducing a Ca2+ entry into
the cells.
It is known that LPC acts on various intracellular signalling
pathways [27]. In order to understand the activation mechanism of
LPC, we used different inhibitors of intracellular signalling pathways.
10 μM U73122, a PLC inhibitor, had no effect on the LPC response (Fig.
4D). The pretreatment with 50 μM PI3,4K inhibitor wortmannin (Fig.
4D) for 15 minutes had a weak effect on Ca2+ entry induced by LPC
10 μM (521 nM±31 nM) in CHO-mTRPV2 cells. However, pretreatment
with wortmannin 150 μM (the dose-effect curves of wortmannin are
presented in the supplementary data, Fig. 5), or with another PI3,4K
inhibitor LY294002 50 μM for 15 min, respectively, drastically
inhibited the LPC effect (Fig. 4D) (15 nM±5 nM) or partially inhibited
the LPC effect (Fig. 4D) (141 nM±26 nM) on CHO-mTRPV2 cells. In
order to check whether LPC effect is mediated by G-protein, we used
pertussis toxin (PTX), an inhibitor of Gi and Go proteins [28].
Pretreatment with 250 ng/ml PTX for 12 h abolished the Ca2+ entry
induced by LPC on CHO-mTRPV2 (Fig. 4D 7 nM±3 nM). We also tested
the effects of the same molecules on the hTRPV2 channel. Pretreat-
ment of HEK-hTRPV2 cells with 50 μM LY294002 for 15 min or with
PTX 250 ng/ml for 12 h also blocked the Ca2+ entry induced by LPC (Fig.
4E, 117 nM±5 nM and 3 nM±1 nM, respectively). Therefore, the
activation of the TRPV2 channel by LPC is mediated by G-proteins and
the PI3,4K pathway.e pSilencer empty vector (HEK-hTRPV2) (I) are analyzed 72 h later for GFP ﬂuorescence
I). GFP ﬂuorescence is totally abolished when cells are nucleofected (72 h) with hTRPV2/
V2shV2 I and II cell lysates with the anti-GFP antibody showing hTRPV2 expression 72 h
intensities of the bands. (IV). (B) Confocal images showing (I) co-localisation for GFP (II)
Ca2+ imaging showing the effect of high temperatures (indicated by red bars) in HEK-
e traces measured by Ca2+ imaging showing the effect of LPC 10 μM in HEK-hTPV2 cells
riment showing the effect of LPI 10 μM in HEK-hTPV2 cells (N=60; n=3), and in HEK-
in response to LPC 10 μM (N=60; n=3), LPI 10 μM (N=60; n=3) and methanol (MeOH)
f the current (measured at ±100 mV) changes in response to LPC (3 μM) in HEK-hTRPV2
ctivation of hTRPV2 current by LPC (3 μM).
Fig. 3. Screening of various lysophospholipids on TRPV2 activity. (A) Comparative graph obtained by Ca2+ imaging showing maximal mean (Δ[Ca2+ cyt]) in response to LPC (N=90;
n=3) as control, a mix of fatty acids (N=90; n=3), choline (N=90; n=3), S1P (N=90; n=3), LPA (N=90; n=3) and LPE (N=60; n=3) in CHO-mTRPV2 cells. (B) Ca2+ imaging experiment
showing maximal mean in response (Δ[Ca2+ cyt]) to LPC (N=60; n=3) as control, a mix of fatty acids (N=60; n=3), choline (N=60; n=3), S1P (N=60; n=3), LPA (N=60; n=3) and LPE
(N=60; n=3) in HEK-hTRPV2 cells. (C) Comparative graph showing Δ[Ca2+ cyt] in response to LPC CTL 10 μM (N=60, n=3), LPC C18:1 (N=60, n=3), LPC C18:0 (N=60; n=3), LPC C16:0
(N=60; n=3), LPC C14:0 (N=60; n=3), LPC C12:0 (N=60; n=3) and LPC C6:0 (N=60; n=3) in CHO-mTRPV2 cells. (D) Ca2+ imaging experiment showing Δ[Ca2+ cyt] in response to LPC
CTL 10 μM (N=60, n=3), LPC C18:1 (N=60, n=3), LPC C18:0 (N=60; n=3), LPC C16:0 (N=60; n=3), LPC C14:0 (N=60; n=3), LPC C12:0 (N=60; n=3) and LPC C6:0 (N=60; n=3) in HEK-
hTRPV2 cells. All lysophospholipids molecules were used at 10 μM concentration.
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In order to check if the Ca2+ inﬂux via TRPV2 channel is due to an
increased plasma membrane channel expression, we performed cell
surface biotinylation (Fig. 5A, n=3). When cells were stimulated with
LPC, the amount of mTRPV2 expressed in the biotinylated fraction
markedly increased (Fig. 5A). As PTX and LY294002 inhibited the Ca2+
entry induced by LPC, we studied their effect on mTRPV2 transloca-
tion. Pretreatment with 250 ng/ml PTX only or with 50 μM LY294002
had aweak effect, but these pretreatments abolished the LPC effect on
TRPV2 plasma membrane translocation (Fig. 5A). The cell surface
expression of hTRPV2 was increased when 10 μM LPC was applied in
HEK-hTRPV2 (Fig. 5B, n=3).
3.5. LPC and LPI stimulate endogenous TRPV2 and induce cell migration
Semi-quantitative RT-PCR and immunoblotting analysis of the
human prostate cancer cell PC3 line revealed a high level of TRPV2
expression (Fig. 6A, B). TRPV2 silencing with shRNA TRPV2 I and II
(PC3 shV2 I and II) abolished the channel expression both on mRNA
(Fig. 6A) and protein levels (Fig. 6B) compared to PC3 nucleofected
with the empty pSilencer vector (PC3 pSil cells).
By using Ca2+ imaging, we have demonstrated that 10 μM LPC and
10 μM LPI induce a Ca2+ entry in PC3 pSil cells, but not in PC3 shV2 Iand II (Fig. 6C and D). However, PC3 cells expressed other TRP
channels such as TRPV1, which is known to be sensitive to lysopho-
spholipids [17,29,30]. In order to ensure that LPC and LPI effects were
speciﬁc for TRPV2 channel, we applied 10 μM capsazepin, an inhibitor
of TRPV1. In the presence of capsazepin, LPC and LPI still induced an
increase in the Ca2+ inﬂux which was abolished with the TRPV2
silencing. This proves that LPC and LPI act on the endogenous TRPV2
channel, expressed in PC3 cells, providingCa2+ entry. It has been shown
previously that lysophospholipids induced PC3 cell migration [31–33].
We have demonstrated using a migration protocol that basal cell
migration was decreased in PC3 shTRPV2 I and in PC3 shTRPV2 II cells
compared to PC3 pSil cells (89±5 cells for PC3 pSil cells, 59±10 cells for
PC3 shTRPV2 I cells, 58±12 cells for PC3 shTRPV2 II cells, Fig. 6E).
Moreover, we have shown that both 10 μM LPI and LPC induce an
increase in cell migration of PC3 pSil cells (Fig. 6E, 103±4 cells for LPI,
108±6 cells for LPC, compared to control H2O condition 89±5 cells).
However, lysophospholipid effects on cell migration are totally
abolished in PC3 shTRPV2 I cells (52±5 cells for LPI and 48±7 cells
for LPC) and in PC3 shTRPV2 II cells (respectively 51±5 cells for LPI and
43±8 cells for LPC).We have demonstrated that a higher concentration
(20 μM) of LPC and LPI induced a decrease of PC3 pSil cell migration by
10±12% and 55±12% respectively compared to control H2O condition
(Fig. 6F). Moreover, we have shown that pretreatment with LY294002
(50 μM) decreased cell migration by 25±14% compared to control H2O
Fig. 4. Basic characterization of TRPV2 by Ca2+ imaging. (A) LPC induced a slight depletion of Ca2+ store in Ca2+ free condition (HBSS 0Ca2+) and a strong Ca2+ inﬂux in presence of
2 mM Ca2+ in CHOmTRPV2 (N=60; n=3), (B) as for HEK-hTRPV2 cells (N=60; n=3). LPC has no effect on CHO or HEK control cells (A, B) (N=60; n=3 per condition). (C) Comparative
graph showing Δ[Ca2+ cyt] in response to LPC in the absence of Ca2+ (HBSS 0Ca2+) and in the presence of 2 mM Ca2+ in CHO-mTRPV2 and in HEK-hTRPV2 cells (N=60; n=3 per
condition). (D) Ca2+ imaging experiment showing that pretreatment with 10 μMU73122, 30 min, has no effect on the amplitude (Δ[Ca2+ cyt]) of LPC response but pretreatment with
50 μM wortmannin, 15 min, has a weak effect on this amplitude. Moreover, pretreatment with wortmannin 150 μM or with 50 μM LY294002 for 15 min drastically diminished the
amplitude of the response induced by LPC in CHO-mTRPV2 (N=60; n=3). The characteristic traces are shown in the inserted panel (N=60; n=3 per condition). Pretreatment with
PTX 250 ng/ml overnight abolished LPC response in CHO-mTRPV2 cells (N=60; n=3 per condition). (E) Comparative graph showing that pretreatment with 250 ng/ml PTX overnight
or with 50 μM LY294002 15 min, totally inhibited the amplitude (Δ[Ca2+ cyt]) of LPC response in HEK-hTRPV2 cells. The characteristic traces are shown in the inserted panel (N=60;
n=3 per condition).
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Fig. 5. LPC induces translocation of TRPV2 to the plasma membrane. (A) Immunoblotting with the anti-mTRPV2 antibody showing increase in mTRPV2 expression in the biotinylated
fraction after LPC (10 μM) application on CHO-mTRPV2 cells (n=3). This increase was abolished by pretreatment with 50 μM LY294002 or 250 ng/ml PTX (overnight). Pretreatment
only with 50 μM LY294002 or 250 ng/ml PTX (overnight) has a weak effect. The numbers indicated under the biotinylated fraction panel are the relative integrative intensities of the
bands. (B) Immunoblotting with anti-hTRPV2 antibody showing increase in hTRPV2 expression in biotinylated fraction from 10 μM LPC treatment (n=3). The numbers indicated
under the biotinylated fraction panel are the relative integrative intensities of the bands.
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migration (Fig. 6G).
4. Discussion
In our study we investigated phospholipids as potential physio-
logical activators of TRPV2 channels and we found that lysopho-
spholipids, LPC and LPI, are able to stimulate mTRPV2 as well as
hTRPV2. More precisely, LPC and LPI generated a Ca2+ entry by
inducing the translocation of TRPV2 protein to the plasma mem-
brane. Our results showed that activation and translocation of TRPV2
by lysophospholipids are mediated by G proteins and P13,4K
pathways. Moreover, we have demonstrated that in TRPV2 expres-
sing prostate cancer PC3 cells, LPC and LPI increased cell migration,
while TRPV2 silencing drastically diminished the lysophospholipid-
induced effect.
LPC and LPI stimulated both murine and human TRPV2 homo-
logues, suggesting common activation mechanisms for mTRPV2 and
hTRPV2. However, 2-APB and high temperatures stimulated mTRPV2,
but not hTRPV2. Such divergence in modes of activation between the
human and murine TRPV2 homologues has been previously observed
by Neeper et al. [14]. The authors suggest that both the NH2- andCOOH-terminal regions appear to be important for channel activation
by 2-APB and high temperature [14].
LPC and LPI are widely found in biological systems and are
considered to have a broad range of physiological and pathological
effects [34–38]. We have shown that lysophospholipid application
induces a rapid [Ca2+]cyt increase. Importantly, our results show that
TRPV2 activation depends on the length of the unsaturated chain of
the fatty acid and, moreover, that lysophospholipids need a speciﬁc
combination of head-group composition and side chain length to
stimulate the TRPV2 channel.
To date, there are two main hypotheses explaining lysopho-
spholipidic actions: (i) indirect action via a receptor for the LPA or the
sphingosine [39]; (ii) direct action (as was suggested for the LPC effect
on the TRPC5 channel [16,40]). Indeed, TRPC5 was considered as a
direct sensor of lysophospholipids, a lipid ionotropic receptor.
However, apparently in our case, lysophospholipid stimulation can
be mechanistically attributed to signalling through speciﬁc G protein-
coupled receptors. Lysophospholipids do not directly activate TRPV2
channels like a lipid ionotropic receptor. That is probably why we
observed a Ca2+ increase induced by LPC or LPI via TRPV2 channel after
some delay. The stimulatory effect of lysophospholipids on TRPV2
should be distinguished from those of 2-APB and high temperature
Fig. 6. LPC effects on the cell migration of the prostate cancer cell line PC3. (A) Silencing of TRPV2 expression in human prostate PC3 cells nucleofected with shTRPV2 I or II (PC3
shTRPV2 I or II) or empty vector (PC3 pSil). (B) Immunoblotting with antibody anti hTRPV2 showing that expression of TRPV2 protein in PC3 shTRPV2 I or II cells is abolished
compared to PC3 pSil cells. The numbers indicated under the hTRPV2 panel are the relative integrative intensities of the bands. (C) 10 μMLPC induces cytoplasmic Ca2+ increase in PC3
pSil, but not in PC3 shTRPV2 I or II cells (N=90; n=3 per condition). (D) 10 μM LPI induces cytoplasmic Ca2+ in PC3 pSil, but not in PC3 shTRPV2 I or II cells (N=90; n=3 per condition).
(E) 10 μM LPC and/or LPI induces cell migration increase in PC3 pSil. Cell migration in control are reduced in PC3 shTRPV2 I or II cells (n=3). Increases of cell migration induced by LPC
and LPI are abolished in PC3 shTRPV2 I or II cells (n=3), (F) or by a higher concentration (20 μM) of LPC and/or LPI in PC3 pSil cells (n=3). (G) Pretreatment with 50 μM LY294002
decreased PC3 cell migration and abolished effect of LPC on those cells (n=3).
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potentialise mTRPV2 current already activated by 2-APB.
Our data suggest that lysophospholipids act on TRPV2 channels by
the PI3,4K pathway, inducing the translocation of the channel to the
plasma membrane. It is known that lysophospholipids could activate
PI3,4K [39] and it has been suggested that these kinases are involved
in TRPV2 activation [10]. Moreover, it has been shown that the
chemotactic peptide fMetLeuPhe, a potent inducer of leucocyte
chemotaxis and a macrophage activator, induces translocation of the
TRPV2 channel via the PI3K pathway in macrophages [8]. However,
the results on TRPV2 translocation towards the plasma membrane
seem to be a controversial issue [41]. Indeed, it has been suggested
that PI3K promotes TRPV2 activity independently of the channel
translocation to the plasma membrane [10]. Furthermore, wortman-
nin and LY294002 at high concentrations were shown to inhibit the
PI4K pathway [42,43]. Therefore, the insertion of TRPV2 into the
plasma membrane could be regulated by PI4K and not by PI3K. It is
important to note that the optimal speciﬁcity of the pharmacological
agents may always be in question, therefore other tools such as
siRNAs, mutants, or more speciﬁc pharmacological agents should be
considered. In addition, a TRPV2 partner called recombinase gene
activator protein (RGA) has recently been identiﬁed by an interaction
trap screening. The binding of RGA to TRPV2 promotes its surface
expression, in a protein kinase A-dependent way [41]. Finally, it has
been proposed that Ca2+ could be involved in such a dynamic
regulation of TRPV2 [44] by promoting the channel's activity and
therefore Ca2+ inﬂux. This suggests that other intracellular pathways
could be involved in TRPV2 plasmamembrane expression. It should be
noted that the heterogeneity in the kinetics of [Ca2+]i increase
following lysophospholipid application has been observed in our
study (Fig. 4A,B). This ﬁnding could be explained by the differential
amount of TRPV2 presented in the plasma membrane before the
translocation stimulated by lysophospholipids.
We also demonstrate that LPC and LPI generate Ca2+ inﬂux in the
human prostate cancer cell line PC3 which expresses TRPV2
endogenously. It has been suggested that lysophospholipids are
signiﬁcant actors in tumour development, since they stimulate
angiogenesis, growth, survival and migration of malignant cells
from various origins [31–33] such as the ovary or the prostate
[45,46]. Lysophospholipids were reported to be present in the
micromolar range in these tissues [34,35] corresponding to the
concentration which in our study was effective to induce calcium
entry and to stimulate migration of cancer cells. However, high
concentrations of lysophospholipids seemed to be cytotoxic. Recently,
it has been shown that TRPM8 channels cloned from human prostate
and known to be involved in prostate tumour development are also
activated by lysophospholipids, acting as endogenous ligands of the
channel [17].
TRPV2 is a physiological sensor of hot temperatures [47]. However,
temperature alone is unlikely to account for activation of TRPV2 in all
tissues [48]. TRPV2 is also expressed in non-neuronal cells such as the
prostate [6] or human blood cells, suggesting that, in addition to its
role as a noxious heat sensor [47], this channel certainly encompasses
other cellular functions [49]. Previously, TRPV2 activation has been
shown to be involved in macrophage cell migration [8]. The authors
demonstrated that the chemotactic peptide fMetLeuPhe induces the
migration of macrophages and that this migration is linked to the
translocation of the TRPV2 channel via PI3K pathway. In accordance
with these ﬁndings, our results on human prostate cancer cells
strongly suggest TRPV2 as being a signiﬁcant actor in cancer cell
migration. Indeed, silencing with shRNA TRPV2 or inhibition of PI3,4K
pathway abolished the stimulatory effect of lysophospholipids on both
calcium entry and migration.
It is important to note that neurons and non-neuronal cells
hardly ever experience the high temperatures which are generally
considered to stimulate TRPV2 (N53 °C). Endogenous modulators,such as lysophospholipids, could lower the temperature threshold
so that TRPV2 can operate at physiological body temperatures. In
conclusion, these lipid modulators could therefore have two roles:
setting the temperature sensitivity of heat receptors in neurons and
regulating cell migration in non-neuronal tissues. Considering that
cancer cell migration remains one of the less understood processes
leading to cancer progression and that currently there is no
treatment speciﬁcally targeting migrating cells, our ﬁndings
provide new insight into the role of TRPV2 in cancer progression
and may be of great importance in developing new therapeutic
strategies.
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